CN-121971494-A - Probiotic composition for preventing and treating respiratory tract infection, application and product thereof

Abstract

The invention belongs to the technical field of biological medicines, and discloses a probiotic composition for preventing and treating respiratory tract infection, and application and a product thereof. The probiotic composition provided by the invention contains bifidobacterium longum subspecies infantis i18 and lactobacillus paracasei N1115. Compared with other combinations of bifidobacteria and lactobacillus paracasei, the specific combination of bifidobacterium longum subspecies i18 and lactobacillus paracasei N1115 not only has better adhesion capability to airway epithelial cells, but also can remarkably reduce inflammatory response of inflammatory cells, effectively repair injured airway epithelial cells, and the two also show better synergistic effect in inhibiting staphylococcus aureus growth. After the breast milk oligosaccharide is added on the basis, the adhesion capability to respiratory epithelial cells and the antibacterial activity to target pathogenic bacteria can be further enhanced. The invention can be applied to the fields of preparing related foods or medicines for preventing, treating or assisting in treating respiratory tract infection, and the like.

Inventors

• WANG XINCHAO
• FENG LILI
• ZHANG DONG
• FENG XIAOYING
• SHENG NAN
• Zhao Jiejing
• LIU HAIRONG
• WANG SHIJIE

Assignees

• 君乐宝乳业集团股份有限公司

Dates

Publication Date

20260505

Application Date

20260104

Claims (10)

1. 1. A probiotic composition for the prevention and treatment of respiratory tract infections, characterized in that it comprises Bifidobacterium longum subspecies infantis i18 and Lactobacillus paracasei N1115.
2. 2. The probiotic composition for preventing and treating respiratory tract infection according to claim 1, wherein the ratio of viable count of bifidobacterium longum subspecies infantis i18 to viable count of lactobacillus paracasei N1115 is 1:10 to 10:1.
3. 3. The probiotic composition for the prevention and treatment of respiratory tract infections according to claim 1 or 2, characterized in that the probiotic composition further comprises breast milk oligosaccharides.
4. 4. The probiotic composition for the prevention and treatment of respiratory tract infections according to claim 3, characterized in that said breast milk oligosaccharide comprises at least one of 2 '-fucosyllactose, lacto-N-neotetraose, lacto-N-tetraose, 3-fucosyllactose or 6' -sialyllactose.
5. 5. The probiotic composition for the prevention and treatment of respiratory tract infections according to claim 4, characterized in that said breast milk oligosaccharide is 2' -fucosyllactose.
6. 6. The probiotic composition for preventing and treating respiratory tract infection according to claim 4 or 5, wherein the weight ratio of the breast milk oligosaccharide in the probiotic composition is 16% -35%.
7. 7. A probiotic food product, characterized in that it comprises a probiotic composition according to any one of claims 1 to 6.
8. 8. A pharmaceutical product comprising the probiotic composition according to any one of claims 1 to 6.
9. 9. Use of a probiotic composition according to any one of claims 1 to 6 for the preparation of a food product for the prevention or adjuvant treatment of respiratory tract infections.
10. 10. Use of a probiotic composition according to any one of claims 1 to 6 for the preparation of a medicament for the prevention, treatment or co-treatment of a respiratory tract infection.

Description

Probiotic composition for preventing and treating respiratory tract infection, application and product thereof Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to a probiotic composition for preventing and treating respiratory tract infection, and application and a product thereof. Background The respiratory tract is used as an open cavity for the human body to communicate with the outside, and the mucous membrane surface is exposed to various external stimulus factors such as microorganisms (including bacteria, viruses, fungi and the like), dust, pollutants and the like at any time, so that the respiratory tract is an important defense barrier of the immune system of the human body. The related epidemiological research reports clearly indicate that mortality directly or indirectly related to respiratory tract infections is the fifth leading cause of global overall death, whether it is a susceptible population such as children, the elderly, or immunocompromised population, is faced with serious health risks associated with respiratory tract infections, not only reducing the quality of life of the patient, but also increasing social medical burden. In current clinical practice, antibiotics are the most commonly used and widely used means for treating bacterial respiratory infections, and have played an important role in controlling the spread of infection and alleviating the disease. However, as the unreasonable use and abuse of antibiotics become more prominent, a series of problems are raised. Under the background, searching for a safe, effective and difficult-to-produce respiratory tract infection prevention and treatment means becomes one of the research hotspots in the medical field. In recent years, more and more researches show that a close intestinal-lung axis regulation mechanism exists between intestinal tracts and respiratory tracts, probiotics can regulate the balance of an intestinal immune system through being fixedly planted in intestinal mucosa, and further indirectly influence the function of the respiratory tract immune system through the signal transduction function of the intestinal-lung axis, enhance the barrier function of the respiratory tract mucosa, promote the activation of immune cells and the secretion of cytokines, thereby playing a certain role in preventing and assisting in improving respiratory tract infection. However, the effect of probiotics has high strain specificity, and probiotics of different species and different strains have obvious differences in metabolites, colonization capacity and action mechanism, so that the effects of probiotics on preventing and treating respiratory tract infection are different. Meanwhile, the single strain probiotics commonly used in the existing research are difficult to form a synergistic effect due to the fact that the action targets are relatively single, and have large limitations on the immunoregulation effect and the anti-infection effect, so that the requirements of clinical high-efficiency respiratory tract infection prevention and treatment products cannot be met. Therefore, screening of the probiotic strains with definite synergistic effect and construction of the probiotic composition with better effect become key problems to be solved urgently in the field of application of the probiotics to respiratory tract infection prevention and treatment. Disclosure of Invention In view of the above-mentioned problems with the prior art, the present invention provides a probiotic composition for the prevention and treatment of respiratory tract infections, and uses and products thereof. The invention creatively discovers that the combination of the bifidobacterium longum subspecies i18 and the lactobacillus paracasei N1115 can be well adhered to bronchial epithelial cells, promote secretion of inflammatory factors and repair cell injury, and can be used for preventing and treating upper respiratory tract infection. In order to achieve the above purpose, the embodiment of the invention adopts the following technical scheme: In a first aspect, the present invention provides a probiotic composition for the control of respiratory tract infections comprising bifidobacterium longum subspecies infantis i18 and lactobacillus paracasei N1115. The bifidobacterium longum subspecies i18 provided by the invention is separated from the faeces of new-born infants, and proved by identification to belong to Bifidobacterium longum subsp.infantis, the strain is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) on the 7 th month of 2024, the preserving unit address is North Star Xili No. 1,3 in the Chaoyang area of Beijing city, and the preserving number is CGMCC No.31411. The strain of the Lactobacillus paracasei (Lactobacillus paracasei) N1115 has the preservation number of CGMCC No.4691, and is disclosed in Chinese p